Arcturus Therapeutics (NASDAQ:ARCT) has been given a $18.00 price objective by stock analysts at HC Wainwright in a research note issued on Friday, TipRanks reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 62.60% from the company’s current price.
Other analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a report on Tuesday, July 16th. Brookline Capital Management reiterated a “buy” rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 24th. Chardan Capital set a $18.00 price objective on shares of Arcturus Therapeutics and gave the company a “buy” rating in a research note on Thursday, June 20th. Finally, ValuEngine lowered shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Arcturus Therapeutics presently has an average rating of “Buy” and an average target price of $15.33.
Shares of NASDAQ:ARCT traded up $0.51 during trading on Friday, reaching $11.07. 69,398 shares of the company’s stock traded hands, compared to its average volume of 61,571. The company has a debt-to-equity ratio of 2.43, a current ratio of 2.51 and a quick ratio of 2.51. Arcturus Therapeutics has a 12 month low of $4.11 and a 12 month high of $15.50. The company has a 50 day moving average of $10.32 and a 200-day moving average of $7.41. The stock has a market capitalization of $151.26 million, a P/E ratio of -5.13 and a beta of 2.36.
A number of institutional investors have recently modified their holdings of ARCT. Highline Capital Management L.P. raised its stake in shares of Arcturus Therapeutics by 356.6% in the 2nd quarter. Highline Capital Management L.P. now owns 217,866 shares of the biotechnology company’s stock valued at $2,057,000 after buying an additional 170,152 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. bought a new position in Arcturus Therapeutics during the second quarter worth $1,227,000. ARK Investment Management LLC boosted its position in Arcturus Therapeutics by 13.7% during the first quarter. ARK Investment Management LLC now owns 927,144 shares of the biotechnology company’s stock worth $6,332,000 after purchasing an additional 111,968 shares during the period. Nikko Asset Management Americas Inc. boosted its position in Arcturus Therapeutics by 102.8% during the second quarter. Nikko Asset Management Americas Inc. now owns 129,974 shares of the biotechnology company’s stock worth $1,227,000 after purchasing an additional 65,875 shares during the period. Finally, Creative Planning bought a new position in Arcturus Therapeutics during the first quarter worth $416,000. 13.32% of the stock is owned by hedge funds and other institutional investors.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.
See Also: Why is total return important?
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.